**Figure 3** Disease progression after follow-up for FSHD1 patients from two groups: LM1 (with the lowest methylation) and HM (with the highest methylation). (A) Mean changes of clinical scores for the LM1 and HM groups. (B, C, D) FSHD clinical score (CS) (B), clinical severity score (CSS) (C), and age-corrected CSS (D) are presented at baseline and follow-up. \( *p < 0.05; \quad **p < 0.01; \quad ***p < 0.001; \quad ****p < 0.0001 \). FSHD1, facioscapulohumeral dystrophy type 1.